AbCellera Biologics Analyst Price Targets

Wall Street analyst price targets and consensus rating for AbCellera Biologics (ABCL).

Price Target Range — 12 Quarters

Analyst Consensus — 10 Analysts

8Buy

2Hold

Consensus RatingBuy# Analysts10Avg. Consensus PT$13Upside to Avg. PT+5.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	UBS	Alice Nettleton	Initiate	Buy	$18
Sep 29, 2026	JP Morgan	Brian Cheng	Initiate	Overweight	$17
Sep 24, 2026	Goldman Sachs	Andrea Newkirk	Reinstates	Neutral	$13
Aug 11, 2026	Truist Securities	Robyn Kamaus	PT Raise	Buy	$12→$30
Aug 6, 2026	Stifel	Stephen Willey	PT Raise	Buy	$8→$9
Aug 6, 2026	Cantor Fitzgerald	Steve Seedhouse	PT Raise	Overweight	$11→$12
Jul 7, 2026	Benchmark	Robert Wasserman	Upgrade	Hold→Buy	$11
May 5, 2026	Cantor Fitzgerald	Steve Seedhouse	Initiate	Overweight	$7
Apr 10, 2026	Jones Trading	Debanjana Chatterjee	Initiate	Buy	$11
Nov 7, 2025	Leerink Partners	Faisal Khurshid	Downgrade	Outperform→Market Perform	$4
Aug 8, 2025	Stifel	Stephen Willey	PT Cut	Buy	$8→$7
Jul 14, 2025	Keybanc	Scott Schoenhaus	PT Raise	Overweight	$5→$10
Jul 7, 2025	Leerink Partners	Faisal Khurshid	Assumes	Outperform	$5
May 16, 2025	Truist Securities	Robyn Karnauskas	PT Cut	Buy	$28→$10
May 9, 2025	Stifel	Stephen Willey	PT Cut	Buy	$10→$8
Apr 16, 2025	Keybanc	Scott Schoenhaus	PT Raise	Overweight	$4→$5
Mar 3, 2025	Benchmark	Robert Wasserman	Maintained	Hold	—
Feb 28, 2025	Stifel	Stephen Willey	PT Cut	Buy	$12→$10
Jan 8, 2025	Keybanc	Scott Schoenhaus	PT Cut	Overweight	$5→$4
Nov 5, 2024	Benchmark	Robert Wasserman	Maintained	Hold	—

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $18

UBS analyst Alice Nettleton initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Buy rating and announces Price Target of $18.

Benzinga Newsdesk

PRO
JP Morgan Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $17

JP Morgan analyst Brian Cheng initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Overweight rating and announces Price Target of $17.

Benzinga Newsdesk

PRO
Goldman Sachs Reinstates Neutral on AbCellera Biologics, Announces $13 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates AbCellera Biologics (NASDAQ:ABCL) with a Neutral and announces $13 price target.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on AbCellera Biologics, Raises Price Target to $30

Truist Securities analyst Robyn Kamaus maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $12 to $30.

Benzinga Newsdesk

PRO
Stifel Maintains Buy on AbCellera Biologics, Raises Price Target to $9

Stifel analyst Stephen Willey maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $8 to $9.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on AbCellera Biologics, Raises Price Target to $12

Cantor Fitzgerald analyst Steve Seedhouse maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and raises the price target from $11 to $12.

Benzinga Newsdesk

AbCellera Biologics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

AbCellera Biologics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $18

PRO
JP Morgan Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $17

PRO
Goldman Sachs Reinstates Neutral on AbCellera Biologics, Announces $13 Price Target

PRO
Truist Securities Maintains Buy on AbCellera Biologics, Raises Price Target to $30

PRO
Stifel Maintains Buy on AbCellera Biologics, Raises Price Target to $9

PRO
Cantor Fitzgerald Maintains Overweight on AbCellera Biologics, Raises Price Target to $12

People Also Watch

People Also Watch

AbCellera Biologics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

AbCellera Biologics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $18

PROJP Morgan Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $17

PROGoldman Sachs Reinstates Neutral on AbCellera Biologics, Announces $13 Price Target

PROTruist Securities Maintains Buy on AbCellera Biologics, Raises Price Target to $30

PROStifel Maintains Buy on AbCellera Biologics, Raises Price Target to $9

PROCantor Fitzgerald Maintains Overweight on AbCellera Biologics, Raises Price Target to $12

People Also Watch

People Also Watch

PRO
UBS Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $18

PRO
JP Morgan Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $17

PRO
Goldman Sachs Reinstates Neutral on AbCellera Biologics, Announces $13 Price Target

PRO
Truist Securities Maintains Buy on AbCellera Biologics, Raises Price Target to $30

PRO
Stifel Maintains Buy on AbCellera Biologics, Raises Price Target to $9

PRO
Cantor Fitzgerald Maintains Overweight on AbCellera Biologics, Raises Price Target to $12